In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
How climate change clues are frozen in glaciers
Quebec targets out-of-province students with big tuition hikes
Canada’s broken information laws keep history in the dark
What students think about the parents’ rights movement
Canada’s billion-dollar wine industry is changing. Here’s why
Why the ‘lottery’ of Canadian immigration undermines the system
The battle over the future of the Banff arts centre
A ‘balance of terror’: The geopolitics of the Israel-Hamas war
Premiers attack Trudeau after carbon tax carve-out
Voices inside Gaza and Israel, in the ‘second stage’ of war
Who is Canada’s new Supreme Court justice?
Indigo turns to a familiar face after a turbulent year
The drama over Alberta’s plan to exit the Canada Pension Plan
Bed bugs are everywhere, here’s why
The Rafah border crossing’s significance for Gaza
The class and cultural divides from French immersion
Supreme Court sides with Alberta on federal environmental law
How AI influences the food we’re eating
The threat of Hezbollah joining the Israel-Hamas war
High interest rates and The Bank of Canada, explained
Create your
podcast in
minutes
It is Free
Front Burner
At Issue
The Daily
Today, Explained
Morning Wire